Navigation Links
Ceregene Reports Data From Parkinson's Disease Phase 2b Study
Date:4/19/2013

Ceregene want to acknowledge the courage of all of the patients enrolled in this very important study and their family members.  We also would like to acknowledge the Michael J. Fox Foundation for Parkinson's Research for their long-term support as we continued the development of this novel neurotrophic factor-based treatment with the potential to improve symptoms and also slow disease progression."  

Raymond T. Bartus , Ph.D., executive vice president and chief scientific officer of Ceregene stated: "While we did not achieve the degree of efficacy we had hoped for in this trial, we are proud that our efforts have helped to establish that gene therapy can provide the enabling technology to safely deliver stable, long-term bioactive protein to targeted sites deep in the human brain and that the Parkinson's disease brain is able to show a positive response to neurotrophic factor stimulation. Hopefully, the information and insight we achieved and shared with the biomedical community will aid in the continuing effort to develop more effective therapies for many of these tragic and dehumanizing neurodegenerative diseases."

C. Warren Olanow , M.D., Chairman Emeritus of the Department of Neurology and Professor of Neuroscience at the Mount Sinai School of Medicine in New York and a clinical advisor to Ceregene noted, "This was an extremely well-conceived and designed study. It is unfortunate for patients that broader benefits from this extremely promising therapy could not be demonstrated in this clinical trial. These results illustrate how difficult it is to establish clinical efficacy with entirely novel therapeutic approaches in complicated neurological diseases. The Ceregene team, its scientific advisors and the participating clinical sites are to be congratulated for that effort and the flawless execution of this difficult scientific study."  &
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
(Date:12/24/2014)... 2014 SoundConnect’s 2015 ... cutting edge communication technology, provide continued education and ... webinar series demonstrates online communication features and benefits; ... conferencing’s most innovative and powerful tools. , According ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Feb. 10 Microdosing or Phase 0 clinical ... an imperative phase of the drug development process ... niche capability providers in preclinical testing and technology ... partnerships and alliances, fuelling growth opportunities in this ...
... an MBA-student organized event, will be held February 19-20 in Philadelphia. ... from Healthcare Services, Investment, Pharma, Biotech, and Medical Device sectors. ... ... 2009 Wharton Health Care Business Conference , an MBA-student organized ...
... DSM Biologics and Crucell N.V. (Euronext, Nasdaq: ... they have entered into an agreement with Bioceros B.V. ... Under the terms of the agreement, Bioceros will be ... the PER.C6(R) cell line located in the European Union.Karen ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... elected to the National Academy of Sciences. He is ... from 14 countries elected "in recognition of their distinguished ... of active members now stands at 2,179. Asner ... Ecology,s first staff scientist. Since coming to Carnegie, Asner ...
... Chase, MDResearchers claim to have calculated for the first ... above which the associated risk for cardiovascular events or ... for publication in The Endocrine Society,s Journal of ... There is increasing evidence that vitamin D plays a ...
... Ariz., April 30, 2013 Economic growth is expected ... of 2013, say the nation,s purchasing and supply executives ... the remainder of 2013 continue to be positive in ... These projections are part of the forecast issued by ...
Cached Biology News:Carnegie's Greg Asner elected to National Academy of Sciences 2Researchers pinpoint upper safe limit of vitamin D blood levels 2Economic Growth To Continue Throughout 2013 2Economic Growth To Continue Throughout 2013 3Economic Growth To Continue Throughout 2013 4Economic Growth To Continue Throughout 2013 5Economic Growth To Continue Throughout 2013 6Economic Growth To Continue Throughout 2013 7Economic Growth To Continue Throughout 2013 8Economic Growth To Continue Throughout 2013 9Economic Growth To Continue Throughout 2013 10Economic Growth To Continue Throughout 2013 11Economic Growth To Continue Throughout 2013 12Economic Growth To Continue Throughout 2013 13Economic Growth To Continue Throughout 2013 14Economic Growth To Continue Throughout 2013 15
... solution is a highly scalable analysis ... data in a workgroup or an ... over 40 leading pharmaceutical, biotechnology, academic ... Workgroup streamlines genomics research at large ...
... Process Control at its Best: ... Real-Time Monitoring, Online Changes & comprehensive ... range of parameters auch as pH, ... are accessible and changeable online. Profiles, ...
... genome-wide microRNA (miRNA) expression profiling service using ... enable highly sensitive and specific direct detection ... for mature miRNA of all species available ... miRBase database (Release 8.2). Our service is ...
... acid synthetic peptide whose sequences are derived from mouse resistin protein. ... S(21) - S - M - P - L - C ... I - D - K - K - I - K ... be used for neutralization and control experiments with the polyclonal antibody ...
Biology Products: